Uncategorized

August 22, 2022 Imbria Pharmaceuticals to Present Phase 2a Data from the Ninerafaxstat Program at the European Society of Cardiology Congress 2022 BOSTON, Mass., August 22, 2022 – Imbria Pharmaceuticals, Inc., a clinical stage, cardio-metabolic company developing novel therapies designed to enhance cellular energetics, today announced that data from IMPROVE-DiCE, Phase 2a, open-label trial, will be […]

March 24, 2022 Imbria Appoints John Young to its Board of Directors Imbria Pharmaceuticals, Inc., a clinical stage, cardio-metabolic company developing novel therapies designed to enhance cellular energetics, today announced the appointment of biopharmaceutical industry veteran John Young, to its board of directors.   “We are extremely pleased to welcome John to our board of

March 22, 2022 Imbria Pharmaceuticals to Participate at SVB Leerink Biopharma Private Company Connect Imbria Pharmaceuticals, Inc., a clinical stage, cardio-metabolic company developing novel therapies designed to enhance cellular energetics, today announced that Anne Prener, president and chief executive officer, Jai Patel, chief medical officer, and Komal Joshi, chief financial officer will participate in SVB

March 10, 2022 Imbria Pharmaceuticals Strengthens Executive Leadership Team with New Appointments Imbria Pharmaceuticals, Inc., a clinical stage, cardio-metabolic company developing novel therapies designed to enhance cellular energetics, today announced the appointments of Arash Yavari, M.B.B.S., DPhil., M.R.C.P., as chief scientific officer, Hugo Fry as chief commercial officer and Komal Joshi as chief financial officer.   “We are at a

July 19, 2021 Imbria Pharmaceuticals Announces initiation of enrollment in IMPROVE-HCM, a Phase 2 Study Investigating the safety, tolerability, and efficacy of IMB-1018972 (IMB-101) in patients with non-obstructive hypertrophic cardiomyopathy Imbria Pharmaceuticals, a clinical stage biopharmaceutical company developing novel therapies designed to enhance cellular energetics for the treatment of major forms of heart disease and

June 22, 2021 Imbria Pharmaceuticals announces enrolment of the first 10 patients in IMPROVE-DiCE, an exploratory Phase 2 study investigating the impact of IMB-1018972 on cardiac energetics, metabolism and function in patients with type 2 diabetes Imbria Pharmaceuticals, a clinical stage biopharmaceutical company developing novel therapies designed to enhance cellular energetics for the treatment of

May 17, 2021 Imbria Pharmaceuticals Presents Phase 1 and Preclinical Data of IMB-1018972 (IMB-101), an Investigational Cardiac Mitotrope, at the American College of Cardiology 70th Annual Scientific Session & Expo Phase 1 healthy volunteer study demonstrates that oral administration of IMB-101 is well tolerated and exhibits predictable pharmacokinetic characteristics   Pre-clinical study showed that IMB-101